BIOCYTOGEN-B suggests that the A-share issuance has been approved by the Shanghai Stock Exchange's Science and Technology Innovation Board Listing Committee
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, BIOCYTOGEN-B announced that the 38th review meeting of the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee for 2025 was held on September 24, 2025. Based on the results of the meeting, the company's proposal for A-share issuance and listing on the Shanghai Stock Exchange Science and Technology Innovation Board has been approved by the Listing Committee
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments